School of Medical Sciences, Hospital Universiti Sains Malaysia, Kubang Kerian, Kota Bharu, Kelantan, Malaysia.
Department of Internal Medicine, Hospital Universiti Sains Malaysia, Kubang Kerian, Kota Bharu, Kelantan, Malaysia.
BMC Nephrol. 2022 Sep 9;23(1):310. doi: 10.1186/s12882-022-02935-z.
Performing percutaneous renal biopsy procedures in lupus nephritis (LN) and nephrotic syndrome presents a unique challenge to the nephrologist because of the risk of bleeding from the procedure and the hypercoagulable state in hypoalbuminemia. The management of a patient with venous thrombosis with perinephric hematoma post renal biopsy can be difficult if occurred.
We are presenting a case of perinephric hematoma following percutaneous renal biopsy in a 23-year-old man with lupus nephritis, nephrotic syndrome, and lower limbs deep vein thrombosis (DVT). The patient developed persistent frank haematuria, flank pain and acute urinary retention post-procedure. We have withheld his oral warfarin three days before the procedure, and no anticoagulation was given subsequently. Initial CT Angiography (CTA) renal showing stable hematoma and no visible evidence of vascular injury. Three weeks later, the patient still has persistent frank haematuria and a repeated CTA renal revealed new bilateral renal vein thrombosis. Considering the high risk of worsening symptomatic venous thrombosis, we gave subcutaneous enoxaparin sodium and restart oral warfarin despite ongoing haematuria. The frank haematuria resolved within two days of anticoagulation with no radiological evidence of worsening of the perinephric hematoma. The follow-up ultrasonography a month later showed resolution of the hematoma and renal vein thrombosis with no adverse effect.
Our experience, in this case, highlighted the importance of case selection for percutaneous renal biopsy among high-risk patients. Additionally, a prolonged frank haematuria in post-renal biopsy with nephrotic syndrome warranted a reassessment, as a clinical presentation of post-procedure perinephric hematoma and renal vein thrombosis can overlap. We also demonstrated that restarting anticoagulation earlier than four weeks in a patient with renal vein thrombosis and post-renal biopsy perinephric hematoma can be safe in the selective case.
在狼疮性肾炎 (LN) 和肾病综合征患者中进行经皮肾活检术会给肾病医生带来独特的挑战,因为存在出血风险和低白蛋白血症下的高凝状态。如果发生肾活检术后肾周血肿合并静脉血栓形成,患者的管理可能会很困难。
我们报告了一例狼疮性肾炎、肾病综合征和下肢深静脉血栓形成(DVT)患者经皮肾活检术后肾周血肿的病例。该患者在术后出现持续肉眼血尿、腰痛和急性尿潴留。我们在术前三天停用了他的口服华法林,但术后未给予抗凝治疗。最初的 CT 血管造影(CTA)肾显示稳定的血肿,没有可见的血管损伤证据。3 周后,患者仍持续出现肉眼血尿,重复 CTA 肾显示双侧新的肾静脉血栓形成。考虑到症状性静脉血栓形成恶化的风险较高,我们给予皮下依诺肝素钠并在持续血尿的情况下重新开始口服华法林。抗凝治疗两天内肉眼血尿得到缓解,肾周血肿无影像学恶化证据。一个月后的随访超声显示血肿和肾静脉血栓溶解,无不良影响。
我们的经验强调了在高风险患者中选择经皮肾活检术病例的重要性。此外,肾病综合征患者肾活检术后持续出现肉眼血尿需要重新评估,因为术后肾周血肿和肾静脉血栓形成的临床表现可能重叠。我们还表明,在肾静脉血栓形成和肾活检术后肾周血肿的患者中,早于 4 周重新开始抗凝治疗在选择性病例中是安全的。